Physician profile
Christopher Abshere
NPI 1154320901
$1,005.92
in general payments reported to CMS, 2019-2025
12 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $50.38 · 2021: $85.60 · 2022: $90.53 · 2023: $29.76 · 2024: $211 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544 · Consulting Fee: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.58 |
| Consulting Fee | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $369.64 | 2024-2025 | Airsupra, Flumist Quadrivalent |
| Genentech USA, INC. | $221.72 | 2019-2021 | |
| Radiometer America, INC | $119.00 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $77.73 | 2022 | |
| Pfizer INC. | $70.00 | 2023-2025 | |
| Lilly USA, LLC | $32.10 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $25.28 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.16 | 2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $20.79 | 2025 | |
| Lundbeck LLC | $18.61 | 2021 | |
| Novo Nordisk INC | $15.73 | 2025 | Rybelsus, Ozempic |
| Inari Medical, INC. | $13.16 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Abshere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.